Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.

Literature DB >> 15565349

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.

Pierre D Delmas, René Rizzoli, Cyrus Cooper, Jean-Yves Reginster.

Abstract

Entities: Disease Species

Mesh：

Substances：
Diphosphonates

Year: 2005 PMID： 15565349 DOI： 10.1007/s00198-004-1813-0

Source DB: PubMed Journal: Osteoporos Int ISSN： 0937-941X Impact factor: 4.507

× No keyword cloud information.

27 in total

Review 1. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction.

Authors:
Journal: Osteoporos Int Date: 1998 Impact factor: 4.507

2. The burden of osteoporotic fractures: a method for setting intervention thresholds.

Authors: J A Kanis; A Oden; O Johnell; B Jonsson; C de Laet; A Dawson
Journal: Osteoporos Int Date: 2001 Impact factor: 4.507

3. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation.

Authors: J A Kanis; C C Glüer
Journal: Osteoporos Int Date: 2000 Impact factor: 4.507

4. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors: C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal: Am J Med Date: 2000-09 Impact factor: 4.965

5. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

Authors: J A Kanis; P Delmas; P Burckhardt; C Cooper; D Torgerson
Journal: Osteoporos Int Date: 1997 Impact factor: 4.507

6. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors: S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal: JAMA Date: 1999-10-13 Impact factor: 56.272

Review 7. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.

Authors: P D Delmas; G Calvo; M Boers; E Abadie; B Avouac; A Kahan; J M Kaufman; A Laslop; J F Lekkerkerker; P Nilsson; B Van Zwieten-Boot; G Kreutz; J Y Reginster
Journal: Osteoporos Int Date: 2002-01 Impact factor: 4.507

8. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal: JAMA Date: 1999-08-18 Impact factor: 56.272

Review 9. Diagnosis of osteoporosis and assessment of fracture risk.

Authors: John A Kanis
Journal: Lancet Date: 2002-06-01 Impact factor: 79.321

10. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

Authors: R Recker; J A Stakkestad; C H Chesnut; C Christiansen; A Skag; A Hoiseth; M Ettinger; P Mahoney; R C Schimmer; P D Delmas
Journal: Bone Date: 2004-05 Impact factor: 4.398

12 in total

1. Prevalent vertebral fractures predict subsequent radiographic vertebral fractures in postmenopausal Korean women receiving antiresorptive agent.

Authors: S H Kim; H S Choi; Y Rhee; K J Kim; S-K Lim
Journal: Osteoporos Int Date: 2010-06-09 Impact factor: 4.507

2. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis.

Authors: S Adami; J San Martin; M Muñoz-Torres; M J Econs; L Xie; G P Dalsky; M McClung; D Felsenberg; J P Brown; M L Brandi; A Sipos
Journal: Osteoporos Int Date: 2007-10-16 Impact factor: 4.507

Review 3. Genetics and the individualized prediction of fracture.

Authors: Tuan V Nguyen; John A Eisman
Journal: Curr Osteoporos Rep Date: 2012-09 Impact factor: 5.096

Review 4. Recombinant full-length parathyroid hormone (1-84).

Authors: Marit D Moen; Lesley J Scott
Journal: Drugs Date: 2006 Impact factor: 9.546

5. Bone density, balance and quality of life of postmenopausal women taking alendronate participating in different physical activity programs.

Authors: Cláudio Joaquim Borba-Pinheiro; Mauro César Gurgel de Alencar Carvalho; Nádia Souza Lima da Silva; Alexandre Janotta Drigo; Jani Cléria Pereira Bezerra; Estélio Henrique Martin Dantas
Journal: Ther Adv Musculoskelet Dis Date: 2010-08 Impact factor: 5.346

10. [Treatment of osteoporosis according to the "European Guidance 2008". Fracture-oriented--economical--cost-effective].

Authors: R Bartl
Journal: Internist (Berl) Date: 2008-09 Impact factor: 0.743